Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer

Inclusion Criteria:

1. Histologically or cytologically documented solid tumor

2. Receiving moderately emetogenic chemotherapy for the first time: Patients may bechemotherapy naive, or patients may have previously received a mildly emetogenic agent (such as a taxane) if no nausea/vomiting was experienced with that chemotherapy

3. Scheduled to receive cyclophosphamide </= 1500 mg/m^2 IV and/or doxorubicin >/= 40mg/m^2 IV given as single doses on Day 1. Patients on combination regimens with theseagents are eligible

4. Age >/= 18 years

5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

6. Adequate organ reserve as follows: 1) Hematologic - white blood cell count (WBC) >/= 3000/microL, AGC >/= 1500/microL, platelet >/= 100,000/microL; 2) Renal - Creatinine </= 1.5 times upper limit of normal; 3) Hepatic - Bilirubin and transaminases </= 2.5times upper limit of normal

7. The effects of the three-drug regimen on the developing human fetus are unknown. Forthis reason, women of childbearing potential and men must agree to use adequatecontraception (hormonal or barrier method of birth control; or abstinence) for theduration of study participation. Should a woman become pregnant or suspect she ispregnant while participating in this study, she should inform her treating physicianimmediately.

8. Negative qualitative B-human chorionic gonadotropin (HCG) (pregnancy test)

9. Signed informed consent

Exclusion Criteria:

1. Scheduled to receive highly emetogenic chemotherapy (Hesketh Level 5 - such ascisplatin, streptozotocin, dacarbazine, carmustine, hexamethylmelamine,mechlorethamine, procarbazine) during the study period

2. Scheduled to receive moderately emetogenic chemotherapy (Hesketh Level 3-4) after Day 1 of the study period

3. Experienced nausea and/or vomiting with prior administration of chemotherapy

4. Prior moderately or highly emetogenic chemotherapy: Patients may have previouslyreceived a mildly emetogenic agent (such as a taxane) if no nausea/vomiting wasexperienced with that chemotherapy

5. Scheduled to receive cranial, abdominal, or pelvic radiation therapy during the studyperiod

6. Treatment with any investigational agent within 30 days of randomization

7. Scheduled to receive treatment during the study period with other potential or knownantiemetic agents. Chronically used benzodiazepines may be continued as a singlenightly dose for sleep.

8. Scheduled to receive corticosteroid treatment other than the study drug dose duringthe study period

9. Uncontrolled primary or metastatic CNS tumor (including those with uncontrolledseizures)

10. Other physical causes for nausea or vomiting (such as bowel obstruction) not relatedto chemotherapy administration

11. Recent history of unexplained nausea or vomiting or history of frequent nausea orvomiting

12. Active bacterial or fungal infection for which administration of a corticosteroidwould be contraindicated

13. Hypersensitivity to any of the study agents

14. Sensitivity to sesame oil

15. Planned simultaneous administration of any other investigational agents

16. Pregnant or nursing women

17. Previous poor tolerance of cannabinoids

18. Habitual cannabinoid use or unwillingness to avoid the use of marijuana during thestudy period

19. Previous use of dronabinol or nabilone